Legend Biotech vs Lakefront Biotherapeutics
LEGN and LKFT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LEGN and LKFT compare
Lakefront Biotherapeutics grew revenue faster over the last twelve months (304% versus 59.5% for Legend Biotech).
Lakefront Biotherapeutics scores higher on the StockData Score (7 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LEGN | LKFT |
|---|---|---|
| Size and price | ||
| Share price | $17.50 | $33.98 |
| Change, 1 year | −43.9% | 5.2% |
| Change, 5 years | −68.3% | −34.0% |
| Beta (5Y) | 0.66 | 0.57 |
| Employees | 2,900 | 452 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 59.5% | 304% (better) |
| Revenue growth, 5Y average | 68.8% (better) | 18.4% |
| Net income growth (TTM) | – | 333% |
| EPS growth (TTM) | – | 335% |
| Profitability | ||
| Gross margin | 57.2% | 97.3% (better) |
| Operating margin | −4.3% | 26.5% (better) |
| Net margin | – | 28.8% |
| FCF margin | −9.6% (better) | −24.4% |
| Financial health | ||
| Interest coverage | −2.5× | 285× (better) |
| Current ratio | 3.04 | 20.15 (better) |
| Piotroski F-score | – | 7 |
| Ownership | ||
| Held by institutions | 28.4% | 48.6% |
| Held by insiders | 0.50% | 45.1% |
| Insider net buying, 12 months | −$567K | – |
| Superinvestors holding | 1 | – |
Go deeper
- LEGN stock overview
- LEGN income statement
- LEGN valuation and score
- LKFT stock overview
- LKFT income statement
- LKFT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.